Irish biotech's cancer drug trial cleared to continue

The trial is testing POLB 001, an oral drug designed to prevent cytokine release syndrome (CRS)

Pictured Jeremy Skillington, Chief Executive Officer at Poolbeg Pharma. Picture Jason Clarke

Dublin-based Poolbeg Pharma says its lead cancer immunotherapy drug trial will go ahead unchanged after an interim review of safety data.

The AIM-listed company said a review of the trial's interim safety cohort recommended that the TOPICAL trial continue with no changes to the study protocol. Recruitment is continuing at UK sites, including The Christie in Manchester, The Royal Marsden and University College London Hospitals.